PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Open Access
- 15 February 2019
- Vol. 11 (2), 232
- https://doi.org/10.3390/cancers11020232
Abstract
Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment and improves solubility. The purpose of using Dox is to disrupt the tumor extracellular environment so that PDL-1 antibody can penetrate the tumor core. PDL1-Dox demonstrates significant cell killing, disruption of tumor spheroid and induction of apoptosis in a breast cancer cell line. Significant release of IFN-γ suggests PDL1-Dox can upmodulate T cell activation. Optical imaging of dye conjugate supports the selective tumor targeting ability and core penetration of the construct.Keywords
This publication has 32 references indexed in Scilit:
- Antibody-drug conjugates—an emerging class of cancer treatmentBritish Journal of Cancer, 2016
- Green Synthesis and Characterization of Monodispersed Gold Nanoparticles: Toxicity Study, Delivery of Doxorubicin and Its Bio-Distribution in Mouse ModelJournal of Biomedical Nanotechnology, 2016
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesCancer Immunology Research, 2015
- NF-κB Regulates PD-1 Expression in MacrophagesPublished by The American Association of Immunologists ,2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Cationic lipid-conjugated dexamethasone as a selective antitumor agentEuropean Journal of Medicinal Chemistry, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in MonkeysClinical Cancer Research, 2005